Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Efficacy and safety of pola-ICE, with or without rituximab in relapsed/refractory diffuse large B-cell lymphoma: A real-world multicenter study

View Full Paper
Ask AI
Bookmark
Share

Authors

XZXuanye ZhangHebei Medical UniversityJHJicheng HongSun Yat-sen UniversityRLRui LiuChina Medical University

Discussion

Loading...

Member takes

Implication

Multicenter study shows Pola-ICE improves efficacy in relapsed DLBCL, suggesting it may be a viable treatment option.

Key Points

  • Evaluate the safety and efficacy of Pola-ICE with or without rituximab in relapsed/refractory DLBCL patients.
  • Multicenter retrospective study of 51 R/R DLBCL patients
  • Patients received Pola-ICE regimen with or without rituximab at physician discretion
  • Endpoints included overall response rate (ORR), complete response rate (CRR), progression-free survival (PFS), and overall survival (OS)
  • Best overall response rate was 75.5% with a complete response rate of 42.2%
  • Median progression-free survival was 9.6 months
  • 14 patients achieved complete response showed significantly longer PFS and OS
  • Common Grade 3-4 toxicities included neutropenia (33.3%) and thrombocytopenia (31.3%)

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e29bhttps://doi.org/10.1182/blood-2025-7208
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Polatuzumab Vedotin Combined With R ‐ ICE ( PolaR ‐ ICE ) as Second‐Line Therapy in Diffuse Large B ‐Cell Lymphoma2026
  2. 2Real-world outcomes of polatuzumab, rituximab, and lenalidomide in frail pts with diffuse large B-cell lymphoma.2026
  3. 3Efficacy and safety of pola-based therapy in molecularly defined high-risk DLBCL: A retrospective analysis of real-world data2025
  4. 4Effectiveness and safety profile of pola-based regimen in DLBCL Patients with high-risk factors in real world: A retrospective study in China2025
  5. 5The efficacy and safety of polatuzumab vedotin-based regimens in the treatment of diffuse large B-cell lymphoma: A retrospective real-world study2025